04.03.24 -- Streamline Your Outsourcing Journey & Discover Top CDMOs

Learn how KBI Biopharma is equipped to support drug development and biologics manufacturing and accelerate your timeline. GMP drug substance manufacturing is available in our FDA and PMDA licensed facility at 300L and 2,000L scale, with full release and stability services on site.

Explore Mabion's new installations in upstream development, new bioreactors, as well as downstream development and fill/finish. This state of the art EU-GMP certified facility is staffed by a team of 250 professionals and, as of 2023, is focused solely on providing CDMO services to its clients.

With a strong network of sites across six states and one in Canada, Resilience provides innovative solutions and services for established and emerging therapies. Hear Evan Pasenello, Business Head of Biologics & Vaccines, discuss how Resilience can support your development and manufacturing programs.

Singota Solutions is focused on meeting the needs of small/early stage biotech companies and getting products to patients faster by being agile, accountable, and transparent. Discover Singota’s capabilities in providing formulation development, analytical development, aseptic manufacturing, and supply chain services.

Review the mammalian development services, manufacturing solutions, and Novartis manufacturing sites accessible to external clients. As we expand our mammalian capacity across the manufacturing network, updates on completion dates and capacity availability are presented in the session.

Moving a new biologic or bioconjugate program forward from discovery to market can be a challenging and cumbersome process. Hear expert insight from Abzena’s CTO on how to de-risk and streamline the development of your biopharmaceutical in order to successfully meet your next regulatory or clinical milestone.

Simtra is a premier CMO with a singular focus on sterile injectable drug product form/fill/finish services. Simtra currently has open capacity for liquid vial projects at both manufacturing sites and can support rapid tech transfer depending on the complexity of the project and the availability of raw materials.

Jacob Øgaard presents an update on FDB’s currently available and incoming large scale capacity and capabilities for the drug substance manufacturing of biologics across the CDMO’s global locations in the United States and Europe, with emphasis on their HillerØd, Denmark, and Holly Springs, NC, USA sites.

EirGenix is Taiwan's largest CDMO for mammalian and microbial-derived, clinical, and commercial manufacturing of biologics. We have immediate availability of capacity up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial, and that will increase to 350L and 1,000L by end of this year.

Societal is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, packaging, and logistics services. Senior Vice President and Chief Scientific Officer, Richard Sidwell, Ph.D., delves into Societal’s capabilities and open capacity across sites.

Our experts delve into the advancements in our development and manufacturing capabilities for HPAPI, clinical development, and late-stage projects. Discover how recent expansions of Ajinomoto Bio-Pharma Services, including new labs, flow units, and expanded capacity, can help you to fulfill all your small molecule needs.

Cambrex offers strong expertise in custom development and cGMP API manufacturing for small molecules, including HPAPI, through its Charles City, Iowa facility. Cambrex provides comprehensive analytical and IND-enabling services, as well as drug substance development and manufacturing across the entire drug lifecycle.

Explore Nanoform's CESS technology for nanoparticle generation and the types of particles that can be generated without the need for solvents or excipients. Case studies show how nanoparticles can enable faster onset of oral medications, extend the therapeutic window of long-acting implants, and increase drug loading.

Following FUJIFILM's recent investment in cell therapy services, this presentation offers a glimpse into the flexible, smart designs included in the capacity expansion at the Thousand Oaks facility. Review examples of flexibility and state-of-the art designs to ensure that every cell therapy program can be produced at FDB California.

Learn more about the AGC Biologics’ global Cell and Gene network, track record, capabilities, and how it can provide support for any project. This presentation also provides a detailed look at the North American site in Longmont, Colorado, which specializes in both cell and viral vector gene therapy projects.

With over 25 years of service, Aldevron is a premier CDMO, producing high-quality research and GMP-grade pDNA, mRNA, and protein for drug substance and drug product. Examine our ready-for-use products and review our new capacity for cGMP RNP manufacturing to streamline CRISPR gene editing programs.

BioCentriq offers state-of-the-art facilities, an established track record in GMP drug product release, and customized solutions supported by a seasoned team. Learn how the innovative LEAP platform is spearheading advancements in CAR-T manufacturing and accelerating clinical development timelines.

Gain an overview of the cell and gene manufacturing services provided by Novartis Contract Manufacturing and how the in-house capabilities within our network can support clients' needs in end-to-end production. An update on our new viral vector facility and available capacity are discussed.

Explore our BaseCamp® facility as we share how our unique ecosystem brings together R&D platforms, cGMP manufacturing, and groundbreaking technologies to help enhance speed, delivery, and probability of success to support all stages of cell and gene therapy development and manufacturing.

Discover Forge’s 200,000 square foot, custom-designed cGMP facility dedicated to AAV and plasmid manufacturing. Forge’s end-to-end development and manufacturing capabilities include research-grade production, analytical and process development, toxicology, engineering, and cGMP manufacturing.